The Use of PARP Inhibitors in Ovarian Cancer

EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer

EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer

EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer

EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer

EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer

EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing

EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer

EP: 8.The Role of Novel Targeted Therapies

Now Viewing

EP: 9.The Use of PARP Inhibitors in Ovarian Cancer

EP: 10.Earlier Introduction of Antibody-Drug Conjugates

Video content is prompted by the following:

PARP Inhibitors in Ovarian Cancer Treatment

Key Themes:

• Biomarker-directed PARP inhibitor use in frontline treatment
• Current FDA approvals and indications
• Overall survival concerns in platinum-sensitive settings

Notable Insights:

• Current frontline approvals:
• Olaparib monotherapy maintenance for BRCA1/2 mutations after response to platinum

• Olaparib with bevacizumab for HRD-positive tumors

• Niraparib approved for all-comers whose tumors responded to chemotherapy
• Platinum response serves as a clinical biomarker indicating potential DNA repair deficiency.
• The FDA restricted platinum-sensitive setting approvals to BRCA-positive patients only due to concerns about potential survival detriment in non-BRCA populations.

Dr Moore stated: “PARP inhibitors are the first truly targeted therapy to benefit patients with ovarian cancer...transformative in a biomarker selected way” and noted: “Best place to use them is in frontline...there is the chance we are curing more patients. We believe that.”